

Russia opens its market for bioabsorbable Syntellix implants

Now approved in 70 countries / Further approvals for Singapore and Philippines

Hanover, June 28, 2021. The Russian health authority Roszdravnadzor has approved the use of magnesium-based bioabsorbable implants from the German biomedical & biomaterials pioneer Syntellix. This means that the company's international sales department is now also opening up the market in the largest country in the world in terms of surface area, building on an already existing partnership with a specialized national importer and distributor.

The compression screws and pins, which have now been officially approved for use in Russia for the surgical fixation of bones after an accident and/or for correction of a malposition, are made of the patented alloy MAGNEZIX®; they dissolve into the body after the bone has healed. This eliminates the need for a second surgery to remove the inserted material. As a consequence of an avoided second operation, patients suffer less pain, have fewer sick days and eliminate the corresponding risk of anesthesia or infection from hospital germs. Yet Syntellix implants are similarly stable as comparable old-school products made of titanium or steel; more than 40 scientific publications confirm their efficacy, safety and reliability.

Prof. Dr. Utz Claassen, CEO of Syntellix AG, comments on the successful approval: "Russia is already the 70th country for which the use of our unique magnesium implants for trauma surgery and orthopedics has been approved. With more than 146 million inhabitants, the market is very attractive, especially as the country is investing large sums in modernizing its healthcare system. In addition, since the use of MAGNEZIX® eliminates the need for a second surgery to remove the material, the healthcare system saves money." According to Germany Trade & Invest, the economic development agency of the Federal Republic of Germany, Russia imported more than \$3.8 billion worth of medical technology in 2019, and the Russian Ministry of Industry expects the total market to grow to \$8.4 billion by 2030.

Good news comes also from Singapore, where the Health Sciences Authority has approved the IFSc interference screw, manufactured locally by Syntellix Asia Pte Ltd. This means that the entire portfolio of Syntellix products is now available to patients in the Southeast Asian high-tech-state. In the Philippines, the Ministry of Health has now approved the use of all MAGNEZIX® implants following the first product approval that had already been granted.

About Syntellix:

Syntellix, a Hanover- and Singapore-based global pioneer in biomedical engineering, med-tech, materials & life science that has been honoured with many national and international awards, is the worldwide market leader in the field of bioabsorbable magnesium-based metallic orthopedic implants. The MAGNEZIX® devices developed by Syntellix are described by experts as beneficial for numerous clinical applications, and, according to a published comparative study, they are even "clinically superior" to conventional titanium implants.

Syntellix AG
Aegidientorplatz 2a
30159 Hannover
Germany

T +49 511 270 413 50
F +49 511 270 413 79

info@syntellix.com
www.syntellix.com

Executive Board
Prof. Dr. rer. pol.
Utz Claassen
Chairman of the Executive Board/CEO & Chief Disruption Officer
Dr. rer. pol. oec.
Amir S. Ghoreishi
CFO
Prof. Dr. med.
Martin Kirschner
Chief Medical Officer

Chair of the Supervisory Board
Annette Claassen

Registered Office
Hannover
Amtsgericht Hannover
HRB 202618

For further information:
Pierre Frega
press@syntellix.com

Disclaimer:
This press release is a translation and has been issued for information purposes only. Should there be any discrepancy between this translation and the original German text, the latter shall be the legally binding version.